How the Retatrutide TRIUMPH Phase 3 Program Is Designed

How the Retatrutide TRIUMPH Phase 3 Program Is Designed

The retatrutide TRIUMPH Phase 3 program is designed as a group of separate clinical trials rather than one single study. Individual TRIUMPH trials evaluate retatrutide in different populations and answer different research questions involving obesity, type 2 diabetes, cardiovascular disease, osteoarthritis, obstructive sleep apnea, treatment maintenance, comparative treatment, dose escalation, and cardiovascular or kidney outcomes. Results from one TRIUMPH trial therefore should not automatically be treated as results from the entire program.

This program-level distinction is essential when interpreting retatrutide research. Phase 3 development uses different populations, comparators, durations, and endpoints so that separate clinical questions can be evaluated directly rather than inferred from one obesity trial.

This article is provided for general educational purposes and explains research methods associated with retatrutide and clinical development. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

Retatrutide remains investigational. The existence of Phase 3 results or an active regulatory-development program does not itself mean that the molecule has received regulatory approval.

What Is the TRIUMPH Program?

TRIUMPH is the name used for a group of Phase 3 clinical studies investigating retatrutide in obesity and obesity-related conditions.

The program includes trials designed around different questions involving:

  • body-weight endpoints
  • type 2 diabetes
  • cardiovascular disease
  • knee osteoarthritis
  • obstructive sleep apnea
  • comparative treatment
  • weight-maintenance strategies
  • chronic low back pain
  • dose-escalation strategies
  • cardiovascular and kidney events

The program has expanded over time as new questions have entered clinical development.

Why Phase 3 Uses Multiple Trials

No single trial can answer every clinical-development question reliably.

Different questions may require different:

  • participant populations
  • sample sizes
  • comparators
  • treatment durations
  • endpoints
  • statistical designs

A study designed to measure body-weight change is not automatically capable of establishing cardiovascular-event outcomes.

TRIUMPH-1

TRIUMPH-1 is a Phase 3 study in adults with obesity or overweight without diabetes.

The study uses a randomized, double-blind, placebo-controlled design.

Its master protocol also includes specific participant subsets involving:

  • knee osteoarthritis
  • moderate-to-severe obstructive sleep apnea

This structure allows related but distinct questions to be studied within an organized protocol framework.

What Is a Master Protocol?

A master protocol provides a common framework under which multiple related research questions can be evaluated.

It may coordinate:

  • eligibility procedures
  • treatment allocation
  • common assessments
  • separate population subsets
  • condition-specific endpoints

A master protocol does not mean every participant contributes to every condition-specific analysis.

TRIUMPH-1 Included Condition-Specific Baskets

The TRIUMPH-1 program included subsets of participants with knee osteoarthritis or obstructive sleep apnea.

These subsets permit researchers to assess condition-specific measurements rather than infer those findings from body-weight change alone.

Examples include:

  • osteoarthritis pain measures
  • sleep-apnea measurements
  • body-weight outcomes

The relevant condition-specific endpoint should remain separate from the overall trial endpoint.

TRIUMPH-2

TRIUMPH-2 evaluates retatrutide in adults who have obesity or overweight together with type 2 diabetes.

The study therefore addresses a different population from TRIUMPH-1.

The difference matters because participants with type 2 diabetes may differ in:

  • glucose regulation
  • concurrent medications
  • baseline metabolic measurements
  • weight-change patterns
  • adverse-event context

Results from TRIUMPH-1 and TRIUMPH-2 should not be treated as one interchangeable dataset.

TRIUMPH-2 Also Includes an OSA Subgroup

The TRIUMPH-2 master protocol includes a subset involving obstructive sleep apnea.

This provides another example of condition-specific study design.

An OSA endpoint requires measurements specific to sleep-disordered breathing rather than inference from body-weight change alone.

TRIUMPH-3

TRIUMPH-3 evaluates retatrutide in adults with obesity and established cardiovascular disease.

This population differs from general obesity trial populations because participants already have documented cardiovascular disease.

Study interpretation should consider:

  • baseline cardiovascular risk
  • concurrent cardiovascular medications
  • comorbidities
  • participant age
  • trial-specific eligibility criteria

TRIUMPH-3 Is Not the Same as an Outcomes Trial

A trial involving participants with cardiovascular disease does not automatically become a cardiovascular-outcomes trial.

A cardiovascular-outcomes trial requires endpoints designed around predefined cardiovascular events.

This distinction is important because:

  • population risk is one issue
  • endpoint definition is another

TRIUMPH-4

TRIUMPH-4 studies adults with obesity or overweight and osteoarthritis of the knee.

Its design evaluates both:

  • body-weight-related outcomes
  • knee osteoarthritis pain measurements

This allows the osteoarthritis question to be addressed directly rather than inferred from another trial.

Condition-Specific Endpoints Matter

A valid osteoarthritis study requires a predefined measure of osteoarthritis-related symptoms or function.

Researchers may use validated instruments such as:

  • pain scales
  • WOMAC subscales
  • physical-function measures

Weight change and pain change remain separate endpoints even when both are measured in the same trial.

TRIUMPH-5

TRIUMPH-5 is a Phase 3 head-to-head study comparing retatrutide with tirzepatide in adults with obesity.

Unlike placebo-controlled TRIUMPH trials, this study uses an active comparator.

This design can address comparative questions involving:

  • predefined efficacy outcomes
  • adverse events
  • treatment discontinuation
  • other protocol-defined measurements

A direct head-to-head study provides stronger comparative evidence than comparing numbers from unrelated trials.

Why Head-to-Head Design Matters

Cross-trial comparison can be distorted by differences in:

  • population
  • baseline characteristics
  • study duration
  • endpoint definitions
  • background intervention

A direct randomized comparison reduces many of these problems by evaluating the treatments under one shared protocol.

TRIUMPH-6

TRIUMPH-6 is designed to study maintenance of weight reduction.

The study has a distinct structure involving:

  • an approximately 80-week retatrutide lead-in phase
  • a subsequent randomized, double-blind phase
  • continued retatrutide at defined doses or switch to placebo

This design addresses a different question from initial weight change.

Why Maintenance Requires a Separate Trial

A trial demonstrating change during active treatment does not answer what occurs when treatment strategy changes later.

Maintenance studies can evaluate:

  • continued treatment
  • dose modification
  • treatment withdrawal
  • changes after randomization

These questions require participants who have already completed a defined treatment period.

TRIUMPH-7

TRIUMPH-7 evaluates retatrutide in adults with obesity or overweight and chronic low back pain.

The study uses condition-specific eligibility criteria involving axial-predominant low back pain.

This allows investigators to examine:

  • pain-specific endpoints
  • body-weight outcomes
  • safety

A low-back-pain result cannot be inferred from obesity studies that did not measure the same pain endpoint.

TRIUMPH-9

TRIUMPH-9 is designed to investigate different retatrutide dose-escalation schemes in adults with obesity or overweight without type 2 diabetes.

This Phase 3 study has an enrollment goal of approximately 600 participants and is designed to last about 113 weeks.

The research question focuses on escalation strategy rather than simply comparing retatrutide with placebo.

Why Escalation Strategy Needs Dedicated Research

Participants who reach the same maintenance dose may have different treatment experiences depending on how that dose is reached.

Researchers can compare escalation schemes for:

  • adverse events
  • tolerability
  • discontinuation
  • dose attainment
  • long-term treatment exposure

This cannot be determined solely from the maintenance-dose label.

TRIUMPH-Outcomes

TRIUMPH-Outcomes is a large Phase 3 trial designed around cardiovascular and kidney outcomes.

The study plans to enroll approximately 10,000 adults with:

  • BMI of at least 27
  • atherosclerotic cardiovascular disease
  • and/or chronic kidney disease

Its planned duration extends into 2029.

Why TRIUMPH-Outcomes Is Much Larger

Event-based outcome trials generally require far more participants than studies measuring continuous outcomes such as body-weight change.

Researchers need enough events to compare groups for endpoints involving:

  • serious cardiovascular complications
  • kidney-function deterioration
  • other prespecified clinical events

A larger study can provide statistical power for outcomes that occur less frequently than changes in laboratory or anthropometric measurements.

Surrogate Measures and Event Outcomes Are Different

A trial may find changes in:

  • body weight
  • blood pressure
  • glucose
  • lipids

These findings do not independently establish fewer cardiovascular or kidney events.

TRIUMPH-Outcomes addresses event-based questions directly.

Different TRIUMPH Trials Use Different Comparators

Comparators across the program include:

  • placebo
  • active treatment
  • continued retatrutide
  • switching from retatrutide to placebo

The comparator determines what causal question the trial can answer.

Placebo-Controlled Trials

A placebo-controlled study estimates differences between the investigational regimen and the protocol-defined placebo condition.

It does not directly establish superiority over another active medication.

Active-Comparator Trials

An active-comparator study tests two defined treatments under the same protocol.

Such a design can support direct comparative evidence about the specified endpoints.

It should not be generalized to drugs or doses that were not included.

Randomized Withdrawal Designs

A maintenance study can randomize participants after an initial treatment period.

This design can examine what happens when participants:

  • continue treatment
  • change dose
  • switch to placebo

The result answers a maintenance question rather than an initial-treatment question.

Trial Duration Varies Across the Program

TRIUMPH studies do not all have the same duration.

Longer trials can provide more information about:

  • maintenance
  • later adverse events
  • durability
  • long-term event accumulation

A shorter trial and a multiyear outcomes trial should not be expected to answer the same questions.

Enrollment Size Also Varies

Enrollment depends partly on the primary research question.

Examples range from several hundred participants in focused studies to approximately 10,000 in TRIUMPH-Outcomes.

Sample-size requirements reflect factors such as:

  • expected effect size
  • outcome frequency
  • number of groups
  • statistical precision
  • expected discontinuation

Phase 3 Results Have Begun to Emerge

As of August 2026, Lilly has announced Phase 3 findings from TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3.

TRIUMPH-1 results have also been presented at a scientific meeting.

Detailed TRIUMPH-2 and TRIUMPH-3 results were described by Lilly in July 2026 as topline results awaiting additional scientific presentation and publication.

A company topline announcement and a complete peer-reviewed publication represent different levels of available detail.

Topline Results Require Careful Interpretation

A topline announcement may summarize:

  • primary endpoints
  • selected secondary endpoints
  • selected safety findings

It may not provide the complete:

  • statistical analysis
  • subgroup detail
  • adverse-event tables
  • sensitivity analyses
  • protocol deviations

Detailed publication allows more complete evaluation.

TRIUMPH Is Not the Entire Retatrutide Development Program

Retatrutide development also includes studies outside the TRIUMPH naming family.

For example, separate TRANSCEND studies investigate type 2 diabetes.

This distinction prevents the entire clinical program from being described incorrectly as TRIUMPH.

The Program Can Change Over Time

Clinical-development programs are not static.

Sponsors may:

  • add studies
  • change enrollment estimates
  • update completion dates
  • amend protocols
  • add research questions

Current trial registries should therefore be checked when describing the program.

Trial Registration Matters

Registered trials provide structured information about:

  • study design
  • phase
  • eligibility
  • interventions
  • outcomes
  • enrollment
  • study status

Registry information may be updated as the trial proceeds.

Why Program-Level Interpretation Matters

A single study can answer a focused question.

A development program can address a broader evidence set by combining trials involving:

  • different populations
  • different endpoints
  • different comparators
  • different durations

The evidence should still be evaluated trial by trial before being combined.

What the TRIUMPH Program Can Establish

When its trials are completed and fully reported, the program can provide evidence about defined questions involving:

  • specific obesity populations
  • type 2 diabetes
  • cardiovascular disease
  • osteoarthritis
  • sleep apnea
  • maintenance
  • comparative treatment
  • dose escalation
  • cardiovascular and kidney events

Each conclusion remains connected to the relevant protocol.

What the TRIUMPH Program Does Not Automatically Establish

The existence of a Phase 3 program does not itself establish:

  • regulatory approval
  • suitability for an individual
  • superiority over every alternative
  • absence of rare adverse events
  • results outside the populations studied

Reading a TRIUMPH Trial

Readers may ask:

  • Which TRIUMPH study is being discussed?
  • What population was enrolled?
  • What was the comparator?
  • What were the primary endpoints?
  • How long was the study?
  • Was the question weight change, pain, sleep apnea, maintenance, comparison, or clinical events?
  • Has the study been completed?
  • Are results peer reviewed, presented at a congress, or available only as topline data?

The Lilly TRIUMPH-1 trial record illustrates the master-protocol structure used to evaluate obesity together with separate osteoarthritis and obstructive-sleep-apnea subsets. Current Lilly trial records also document the broader TRIUMPH development program.

Final Perspective

The retatrutide TRIUMPH Phase 3 program should be understood as a portfolio of related but distinct clinical trials.

TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4, TRIUMPH-5, TRIUMPH-6, TRIUMPH-7, TRIUMPH-9, and TRIUMPH-Outcomes address different populations, comparators, endpoints, treatment strategies, and durations.

This structure is scientifically important because weight change, diabetes-related measurements, pain, sleep apnea, maintenance, head-to-head treatment comparison, dose escalation, and cardiovascular or kidney outcomes cannot be established reliably by one trial design. Each result should therefore be interpreted according to the exact TRIUMPH protocol that produced it.

Back to blog